1. Cytokine humanized MISTRG mice reliably engraft lower-and higher-risk MDS 2. MISTRG engraft the clonal MDS stem cells and afford propagation of genetically faithful patient-derived xenografts (PDX) in serial transplantation.
INTRODUCTION
Myelodysplastic Syndrome (MDS) is a group of heterogeneous disorders of the hematopoietic stem cell characterized by recurrent genetic aberrations in genes of essential pathways, including transcription factors, epigenetic regulators, cohesin complex genes, DNA repair genes, and key factors of the spliceosome ( 1,2 and reviewed in 3 ).
Long-term hematopoietic stem cells (HSCs) cannot be expanded in culture and MDS cell lines do not exist, creating an unmet need for in vivo models of MDS. Xenotransplantation of primary human MDS stem cells into currently available immunodeficient mice, such as NOD-scid Il2rg -/-(NSG), has demonstrated limited success with poor and transient engraftment, skewing towards the lymphoid lineage, and engraftment mostly restricted to the injected tibial bone when aided by co-injection of human mesenchymal stem cells (MSC) [4] [5] [6] [7] . Human cytokines provided by constitutive, transgene-driven expression in the NSG-SGM3 model (overexpressing human stem cell factor (SCF), granulocyte-monocyte-colony stimulating factor (GM-CSF), and interleukin-3 (IL3) from a CMV-promoter), improve myeloid differentiation and cellular proliferation, yet stem cell maintenance is impaired [8] [9] [10] [11] . This limitation is overcome transiently by co-injection of autologous human MSC 12 or by creation of an ossicle from human MSC that provides an improved human stem cell environment 13 .
These latter two approaches have limited applicability in pre-clinical studies that require a highly efficient, highthroughput approach.
We here present a novel highly efficient MDS xenotransplantation model, in humanized immunodeficient "MISTRG" mice, expressing humanized M-CSF, IL3/GM-CSF, SIRP alpha, and Thrombopoietin in the Rag -/-, IL2Rγ -/genetic background from their endogenous murine loci. MISTRG mice have previously been shown to be highly permissive for human hematopoiesis and support robust reconstitution of human lymphoid and myelo-monocytic cellular systems 14, 15 . We demonstrate that primary healthy bone marrow-(BM) and MDS
BM-derived CD34 + cells from lower-(IPSS low-and intermediate 1) and higher-(intermediate 2 and high) risk
MDS, defined by the number of cytopenias, blast percentage in BM, and cytogenetic abnormalities, efficiently engraft in MISTRG mice and give rise to multilineage hematopoiesis. We demonstrate that MDS patient-
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RESULTS
MISTRG mice engraft healthy adult bone marrow-derived CD34+ hematopoietic stem and progenitor cells.
Adult CD34 + hematopoietic stem and progenitor cells (HSPC) engraft with significantly lower efficiency in immunodeficient mice compared to human fetal liver-or cord blood-derived CD34 + cells 14 . However, the majority of myeloid malignancies and in particular MDS, occur in the aging adult with quantitative and qualitative limitations to the stem cell population of interest. We transplanted healthy BM-derived CD34 + cells from adult patients, in whom BM involvement by their underlying disease was excluded (see Supplementary   Table 1 ), intrahepatically into newborn NSG and MISTRG mice irradiated with maximum tolerated doses for each strain (Fig. 1a) 14 . The maximum tolerated radiation in NSG mice is limited due to the inherent DNA repair defect conferred by the scid mutation 16, 17 . Samples were CD34 -enriched or CD3 -depleted (Fig. S1a) , and further purged of mature T-cells by pretreatment with the humanized anti-CD3 antibody OKT3 for prevention of graft versus host disease 18 . Highest available, rather than a fixed cell number, were injected as equal splitdonor grafts into NSG and MISTRG mice, to maximize engraftment for each primary sample.
Analysis consisting of complete blood counts and histology (representative subset), and flow cytometry of peripheral blood (PB), bone marrow (BM), and spleen, was performed at least 12 weeks post-transplantation (with few exceptions were analysis was required sooner). Flow cytometric analysis consisted of assessment of overall human leukocyte engraftment (huCD45) as a function of all (murine and human) leukocytes as well as assessment for human erythroid and megakaryocytic engraftment within the murine and human CD45 negative fraction. "Erythroid lineage" engraftment based on CD45 negativity and high transferrin receptor (huCD71) and glyocphorin A (huCD235) expression was quantitated as % of all single live cells ( Fig. 1b) .
MISTRG mice show significantly higher huCD45 + engraftment in PB and BM than NSG mice ( Fig. 1c, d) and support enhanced differentiation towards myelopoiesis ( Fig. 1e) as opposed to lymphopoiesis, modeling a key difference between human and mouse hematopoiesis and as previously shown for mobilized peripheral blood CD34 + HSPCs 14, 19 . CD3 + T-cells represent only a minor fraction within the graft. Interestingly, MISTRG bone marrows show significantly higher numbers of erythroid progenitor cells (CD71 bright , GPA + ) ( Fig. 1f) as well as megakaryocytes ( Fig.1g ). As previously described, expression of human GM-CSF and M-CSF enhance myeloid maturation with differentiation towards mature granulocytes and macrophages ( Fig. 1h, S1b) with repopulation of bone marrow as well as spleen and non-hematopoietic tissues, such as liver ( Fig. S1c) .
In summary, MISTRG mice support superior healthy adult BM xenografts with tri-lineage representation.
MISTRG mice efficiently support PDX from low-and high-risk MDS with multi-lineage output
NSG mice have represented a major breakthrough in xenotransplantation studies due to the lack of mature murine T, B, and functional NK cells 20 and the presence of the Sirpα gene polymorphism, allowing enhanced binding of the mSirpα to human CD47 21, 22 . However, engraftment of MDS BM-derived CD34 + HSPCs remains a challenge, despite several alterations to NSG mice and the transplantation protocol [4] [5] [6] [7] [9] [10] [11] [12] . We engrafted MDS CD34 + (or CD3-depleted) BM cells into NSG and MISTRG recipients as split donor grafts, as in Fig. 1a .
To avoid a priori exclusion of lower-risk MDS samples or patient samples with low cell numbers, CD34 + cells injections for different samples ranged from 0.5x10 5 to 1x10 6 cells per recipient mouse, while maintaining the same cell number for all recipients within each experiment (for detailed patient and sample information see Supplementary Table 1 ).
When plotting engraftment in all mice against injected CD34 + cell number, it is evident, that a minimum number of 1x10 5 CD34 + cells / mouse was required for a reliable engraftment ( Fig. 2a) . Interestingly, increasing cell numbers resulted in improved engraftment in MISTRG while engraftment in NSG recipients remained limited. Although all recipients engrafted above 0.01%, the minimum engraftment threshold set in several studies, for the purpose of pre-clinical modeling a higher engraftment threshold may prove advantageous. When comparing all split donor graphs, engraftment > 1% was achieved in 85% of MISTRG and in 52% of NSG mice. Importantly, engraftment levels >10%, more likely to reliably afford preclinical studies, were achieved in 53% of MISTRG but in less than 10% of NSG mice (Fig. 2b) . MISTRG consistently resulted in higher engraftment than NSG for all MDS subtypes in peripheral blood (top row) and bone marrow (bottom row) ( Fig. 2c -e ). Only 2 out of 28 samples (MDS-MLD Y006, MDS-EB2 Y018), injected at <1x10 5 CD34 + cells/mouse displayed BM engraftment levels < 1% in MISTRG. CD3-depletion of primary MDS BM samples, similar to CD34-enrichment, resulted in similar engraftment levels in PB and BM ( Fig. S2a, b ) and myeloid predominant grafts in MISTRG mice (Fig. S2c) .
Importantly, we here show for the first-time engraftment of primary adult MDS-derived erythropoiesis (defined by huCD71 bright and huCD235 positivity among CD45 neg cells) and megakaryopoiesis (huCD41 + ) in immunodeficient mice, with significantly higher representation in MISTRG mice for all subtypes of MDS ( Fig. 2f-h and Fig. S2d-f ). As described previously for normal hematopoiesis, CD34 + cells from MDS bone marrow give rise to myeloid-predominant, while NSG mice give rise to lymphoid-predominant grafts ( Fig. 2i-k) .
Expression of human M-CSF, GM-CSF, and IL-3 further enhances maturation of MDS-derived myeloid cells with differentiation profiles close to the patients' phenotypes ( Fig. S2g) . To assure that xenografts are derived from the malignant MDS clone we performed mutational analysis by targeted exome sequencing of patient samples and corresponding murine cell-depleted patient-derived xenografts. Presence of corresponding driver mutations at equivalent variant allele frequencies (VAF) confirmed engraftment of MDS-derived hematopoiesis (Supplementary Table 2 ).
The engraftment persisted until the time of analysis, > 12 weeks post-transplantation, without compromising development of anemia or thrombocytopenia in recipients mice (data not shown) or differences in survival between MISTRG and NSG mice (Fig S2h) , with similar engraftment in female and male mice of the respective strains ( Fig. S2i) . Analysis of spleen and non-hematopoietic tissues (shown for liver) confirms functional differences between healthy BM, MDS, and AML xenografts. While healthy BM xenografts engraft BM, liver, and spleen and give rise to resident tissue macrophages in in all three tissues ( Fig. S2j and S3a) , in age-matched patient-derived MDS xenografts these populations are mostly absent from the spleen and the liver, consistent with a functional defect of the myeloid lineages in MDS ( Fig.S2j and S3b ). This is in stark contrast to myeloid leukemia where immature blasts infiltrate spleen and liver ( Fig. S2j and S3c) .
In summary, MISTRG mice support superior long-term, multi-lineage engraftment of MDS cytokinehumanization enhances myeloid lineage maturation and supports erythroid and megakaryocytic lineage development. Furthermore, MISTRG PDX replicate functional differences between healthy, MDS, and leukemia-derived hematopoiesis.
The MISTRG humanized stem cell niche allows propagation of MDS HSC via serial transplantation.
HSCs are critically dependent on the stem cell niche. MDS HSC are dysfunctional and their in vitro and in vivo propagation has been elusive to date. We hypothesized that cytokine humanization of the HSC niche would afford homing and engraftment of primary patient-derived MDS long-term HSC in MISTRG mice capable of serial repopulation. Human thrombopoietin is essential for stem cell function 23, 24 . IL3, GM-or M-CSF are not directly implicated in stem cell maintenance, but via their role in myeloid cell development, such as BM macrophages, they may indirectly supply additional niche signals 25, 26 . We assessed human versus murine cytokine expression ( Fig. 3a, We next determined whether MISTRG mice engraft human HSC via phenotypic and functional assays. In addition to the overall increased engraftment ( Fig. 2, 3c, S4c) , MISTRG support phenotypic HSC as evident by flow-cytometric analysis ( Fig. 3d, e ). CD34 + cells localize along the trabecular bone ( Fig. 3f and S4d) . The clonality of each MDS graft was verified by targeted exome sequencing in representative mice (Fig. S4e, f and Supplementary Table 2 ).
Phenotypic identification of HSCs is insufficient to prove stem cell engraftment. Long-term engraftment (> ~16 weeks) and functional assessment in the form of secondary engraftment are critical. Previous studies have shown successful secondary transplantation of AML 28, 29 and more recently CMML/JMML in NSG and NSG-SGM3 mice 30 but no study has shown successful serial transplantation of MDS. We therefore first tested secondary transplantation of a higher-risk MDS sample according to our standard protocol ( Fig. 3g ). NSG and MISTRG mice were engrafted with high-risk MDS-EB-2 with complex karyotype (Y025) and maintained for > 16 weeks. At time of analysis BM from the highest engrafting mice was enriched for human cells via bead depletion of murine CD45 + and Ter119 + cells ( Fig. S4g, h ) and transplanted intrahepatically into irradiated newborn mice. Secondary recipient mice were analyzed >12 weeks post 2 o transplant. Primary MISTRG recipient mice again showed higher overall engraftment levels ( Fig. 3h ) with myeloid predominance (Fig. 3i) .
Cytogenetic analysis of sorted human cells from NSG and MISTRG primary recipients showed the same complex cytogenetic abnormalities as the patient's ( Fig. S4i) . Interestingly, secondary NSG and MISTRG mice showed similar huCD45 + engraftment in bone marrow ( Fig. 3h) , but again myeloid predominance prevailed in MISTRG, while lymphoid predominance prevailed in NSG secondary recipients ( Fig. 3i) . Notably, MISTRG xenografts contained significantly higher HSC than NSG mice ( Fig. 3j, S4j (Fig. 4a ). Both strains' 2 o recipients successfully propagated clonal MDS for > 16 weeks from 1 o MISTRG donors (15 weeks), however, 2 o NSG engraftment levels were < 1% ( Fig. 4a) with significantly lower percentages of HSC ( Fig. 4b ) and favorable myeloid representation in MISTRG 2 o recipients ( Fig. 4c) . Targeted exome sequencing of primary MISTRG and secondary MISTRG and NSG recipients verified propagation of the patient's clonal MDS ( Fig. 4d, Supplementary Table 2 ). Given the similar VAFs between MISTRG and NSG mice suggests that B-cells in MDS xenografts are derived from the MDS clone. Similar results were obtained with serial transplantation of lower-risk MDS. NSG and MISTRG mice were engrafted with intermediate-1 risk MDS (Y013, MDS-EB1, NK, IPSS int-1, Supplementary Table 1) and their murine-cell depleted bone marrow engrafted after 22 weeks into irradiated recipients of the respective genotypes. Again, NSG secondary recipients showed low-level engraftment (~1%), while MISTRG-derived cells successfully repopulated numerous MISTRG secondary recipients at significantly higher engraftment levels (p<0.001; Fig. 4e ). These engraftment outcomes are again reflected in the phenotypic stem cell frequency in 1 o and 2 o NSG and MISTRG grafts with significantly higher percentage of HSC in MISTRG mice (p< 0.05; Fig. 4f ) with myeloid predominant output Fig. 4g ) MDS clonality of primary and secondary grafts in MISTRG and NSG recipients was again confirmed by targeted exome sequencing ( Fig. 4h) .
Overall, these data suggest, that MISTRG not only provide overall superior engraftment in primary recipients with propagation of the MDS stem cell, but also as secondary recipients. This may at last fill the unmet need for MDS PDX for the study of MDS, allowing the development and testing of novel therapies.
MISTRG mice replicate MDS heterogeneity, myeloid dysplasia, and clonal evolution.
Although several murine models of MDS have been generated, the finding of dysplasia is rare and frequently subtle (reviewed in 31 ). Currently available xenotransplantation models have not been shown to replicate myelodysplasia, the essential diagnostic criterion for MDS, nor to support development of erythroand megakaryopoiesis, two of the three principal cell lines affected in MDS 32, 33 . We engrafted two MDS samples with prominent dysplasia of the megakaryocytic and erythroid lineages, respectively, to evaluate dysplasia in human MDS xenografts. MISTRG mice engrafted with sample Y019 (MDS-EB-1 with normal karyotype, Fig. 5a , left) displayed numerous dysplastic megakaryocytes and reticulin fibrosis, faithfully replicating the patient's MDS dysplastic features ( Fig. 5b) . MISTRG mice engrafted with the same patient's sAML sample obtained at time of disease progression ( Fig. 5a ; Y028, sAML, NK) did not show these features (data not shown). Targeted exome sequencing of the MDS xenografts confirmed derivation from the patient's DNMT3a-mutant MDS clone ( Fig. 5c) . Interestingly, an isocitrate dehydrogenase 1 (IDH1) mutation was identified in several of the MISTRG mice (VAF 18-32%) engrafted with the patient's initial MDS diagnosis sample (MDS-EB-1, Fig. 5c ). This IDH1 mutation was initially not identified in the patient at the time of MDS diagnosis, but present at the time of disease progression to sAML (sAML, VAF 24%, Fig. 5c ). Re-sequencing detected the IDH1 R132C mutation in the MDS diagnosis sample at a VAF of ~1% ( Fig. 5c , middle panel, Supplementary Tables 1 and 2) . Interestingly, in the sAML engrafted MISTRG mice a new NRAS G12S mutation defined the dominant clone, again detectable in the patient's sAML at a VAF <5% upon resequencing, in addition to the dominant DNMT3a and IDH1 mutations. RAS mutations have been described as a potential mechanism of resistance to mutant IDH inhibitor treatment 34 and identification of these mutant clones in a pre-clinical MDS PDX may thus guide the use of pre-emptive combination regimens.
The second patient's BM aspirate (MDS-EB-2, Y025) revealed significant erythroid hyperplasia with erythroid dysplasia and maturation defect ( Fig. 5d top) . Bone marrow aspirate/cytospins of engrafted primary MISTRG and to a much lesser extent of engrafted NSG revealed erythroid precursors with signs of dysplasia, such as binuclear forms (Fig. 5d bottom) . Importantly, BM histology revealed prominent development of huCD235 + erythroid progenitors in MISTRG mice ( Fig. 5e) , confirmed by flow cytometric determination of huCD71 pos and huCD235 pos (gated on CD45 neg , mTer119 neg and huCD45 neg cells) erythroid development as shown in Fig. 5f and quantitated in Fig. 5g . Interestingly, compared to xenografts from healthy BM-( Fig. 5h) and human umbilical cord blood-derived CD34+ HSCPs (Fig. 5i) , erythroid differentiation is left-shifted (to huCD71 hi huCD235 -) in MDS-xenografts with enhanced maturation in healthy BM and UCB ( Fig. 5h, Fig. S5a-d;) . Importantly, erythroid lineage differentiation is always significantly higher in MISTRG than NSG mice, and present in secondary recipients ( Fig. S5e-i) , confirming that it is derived from the MDS stem cell.
In summary, we here show that MISTRG MDS PDX may predict clonal evolution upon disease progression with faithful modeling of the diagnostic dysplasia. Importantly, we present the first MDS PDX model that affords the study of MDS erythropoiesis and megakaryopoiesis in vivo.
MISTRG MDS PDX allow preclinical modeling of targeted therapeutics.
Targeted therapeutics provide novel opportunities for the treatment of MDS, but to date have failed to cure MDS. Recently, inhibitors of mutant IDH1/2 have entered clinical trials, and early data suggest that they result in blast differentiation, but fail to abrogate the mutant clone in the majority of patients [34] [35] [36] . While transgenic murine models can provide proof of principle data, patient-derived xenografts are critical to evaluate efficacy against complex clonal hematopoietic malignancies such as MDS, and are likely to hasten development of valuable combination therapies.
We transplanted MISTRG mice with IDH2 R140Q -mutant MDS-EB-2 CD34 + cells (Y021, Supplementary   Table 1 ) and treated engrafted mice with either vehicle or enasidenib via oral gavage for 30 days. Mice were assigned to enasidenib or vehicle 16 weeks post-transplantation based on equal engraftment levels as determined by BM aspiration (data not shown). Activity of enasidenib was verified in vitro via measurement of 2-hydroxy-glutarate (2-HG) levels in IDH2-wildtype (WT) and -mutant (MUT) expressing human erythroid leukemia (HEL) cell lines ( Fig. S6a ) and primary AML ( Fig. S6b, Y028, Y031 ). Enasidenib efficiently suppressed 2-HG production and inhibited proliferation of IDH2 R140Q -and IDH2 R172K -mutant but not IDH2wildtype AML cell lines (data not shown) and IDH2 R140Q -mutant primary AML compared to vehicle and WT AML ( Fig. S6c) . Enasidenib treatment resulted in differentiation of IDH2 mutant myeloid blasts ( Fig. S6d) .
Treatment with enasidenib, but not vehicle, resulted in myeloid differentiation in the IDH2 R140Q MDS-EB-2engrafted MISTRG mice (Fig. 6a, hCD68 and hCD15 and Fig. 6b ). Overall engraftment levels were significantly reduced in enasidenib treated animals when compared to pre-treatment and vehicle-treated mice ( Fig. 6c ). Of note, enasidenib treated mice also exhibited increased numbers of CD41 + platelets in PB and dysplastic megakaryocytes in BM compared to vehicle treated mice ( Fig. 6a (huCD61), Fig. 6d ). Plasma 2-HG levels in vivo, elevated pre-treatment and in vehicle treated MISTRG mice, were significantly suppressed after administration of enasidenib ( Fig. 6e) . Variant allele frequencies of mutations identified in the patient were represented in all MISTRG mice and not significantly altered by enasidenib treatment (Fig. 6f , Supplementary   Table 2 ).
MISTRG PDX represent the first MDS pre-clinical model that allows to test not only for cytotoxic but also for differentiating effects of targeted therapeutics and capturing multi-faceted responses relevant to clinical success.
DISCUSSION
MDS is a disease of the hematopoietic stem cell and studies of MDS have been hampered by the inability to expand HSCs in general and MDS stem cells in particular. There is an unmet need for an in vivo pre-clinical model to accelerate development of novel treatments for a disease where allogeneic stem cell transplantation currently represents the only cure. Mouse models only partially recapitulate the genetic and epigenetic complexity of patients' MDS. Prior xenotransplantation models have been hampered by preferential engraftment of the remnant normal hematopoiesis 7 , transient engraftment, 6 , and low efficiency 37 . Cytokinehumanization via transgenic expression in the NSG-SGM3 mice, while advantageous in AML 9 and other myeloid malignancies 30 , impairs stem cell function 8, 11 and provides limited advantages over NSG mice for MDS engraftment 37 . Co-injection of human MSC may provide transient support to MDS HSC 12, 37 and generation of a human niche via growth of human MSC-derived ossicles may afford improved engraftment of HSCs 13, 38 and difficult-to-engraft leukemias 38 , but applicability in pre-clinical models at a large scale is likely limited due to technical complexity.
MISTRG mice were engineered to express key non-crossreactive human cytokines from the endogenous murine loci in place of their murine counterparts, thereby providing temporally and spatially physiologic expression of human cytokines. In addition, lack of murine cytokines reasonably provides additional benefit to human hematopoiesis by rendering the stem and progenitor niches in the BM less hospitable to murine HSPC. This is likely to particularly critical to adult HSCs that have markedly lower proliferative and self-renewal capacity than their fetal liver and UCB counterparts (reviewed in 39 ). In addition, MDS stem cells frequently fail to give rise to colony forming units (CFU) in vitro, a manifestation of their defective proliferative and differentiation capacity. Research material from human BMs is limited and worse in aging marrows that are characterized by progressively lower cellularity.
Here, we present for the first time a highly efficient and versatile xenotransplantation model for MDS. We show that MISTRG mice can be engrafted with as few as ~1.5x10 5 Study of adult erythropoiesis and megakaryopoiesis in in vivo models has been elusive to date. MDS is characterized by cytopenias in the peripheral blood, left-shifted myeloid maturation, and erythroid and megakaryocytic dysplasia 3 . Very little is known about the causes of the phenotypic heterogeneity in MDS and genotype-phenotype studies would greatly advance our mechanistic understanding of this complex entity. To date, immunodeficient mouse models have supported erythro-and megakaryopoiesis solely from fetal liverand cord blood-derived HSPCs 40, 41 , further enhanced by mutation of the murine ckit receptor conferring impaired function to murine stem cells [42] [43] [44] and likely murine erythropoietic progenitors 45 . None of these models have supported erythro-and megakaryopoiesis from adult HSPCs. We propose that while cytokine humanization directly enhances overall engraftment and myeloid maturation, lack of the corresponding murine cytokines impairs murine hematopoiesis, thereby synergistically promoting human HSPC competitiveness in the mouse niche. As a result, we here show for the first time development of both erythropoiesis and megakaryopoiesis from healthy adult and MDS BM in a murine host. Intriguingly, MDS -engrafted MISTRG mice replicate the patient's megakaryocytic dysplasia, reticulin fibrosis, and erythroid dysplasia, making MISTRG MDS PDX uniquely suited to assess MDS-associated abnormalities in all three myeloid lineages.
We have previously reported that MISTRG life-span is limited in fetal liver engraftment due to destruction of murine RBC and platelets by human macrophages 14 . Interestingly, MDS-engrafted MISTRG lack significant development of anemia (data now shown) and their life-span is similar to that of engrafted NSG mice ( Supplementary Table 1 ). One possible explanation is the lower engraftment compared to fetal liver HSPC.
Nevertheless, mice engrafted with normal adult CD34 + cells with similar engraftment levels to MDS engrafted mice show evidence of hemophagocytosis by human macrophages ( 19 and data not shown). In contrast to normal CD34 + engrafted MISTRG, MDS PDX lack human derived tissue macrophages in spleen and liver, confirming a functional defect of MDS-derived mature myeloid cells that likely also lack in vivo hemophagocytic activity. Interestingly, MDS blasts, unlike in AML, do not infiltrate non-hematopoietic tissues, functionally distinguishing MDS also from AML in MISTRG PDX.
Cytokine humanization does not alter the lack of mature human red blood cells (RBC) and the low human platelet percentage in the peripheral blood as also shown previously 14, 19 . Administration of human erythropoietin has shown no benefit in this regard 46 as the defect lies in RBC and platelet destruction by the murine innate immune system. Thus modulation of the murine innate immune system will be necessary to promote mature human cell persistence in peripheral blood, transiently achieved by administration of liposomeencapsulated clodronate 41, 47 . In summary, we here present a highly efficient, faithful MDS PDX model, ideally suited for the study of MDS biology, the development of novel treatment approaches, and adaptation of patient-specific regimens in the era of precision medicine.
MATERIALS and METHODS
Human Progenitor Cell Isolation
Peripheral blood, BM, and umbilical cord blood were obtained with donor's written consent. All human studies were approved by the Yale University Human Investigation Committee and by the West Haven Veterans Affairs Human Investigation Committee.
Human BM, cord-blood, and peripheral blood samples were ficolled (GE Healthcare, Munich, Germany) and mononuclear cells cryopreserved within 24 hours after collection in FBS/10% DMSO. Samples were CD34enriched with the CD34-Microbead-Kit or T cell -depleted via negative selection with the CD3-Microbead-Kit (Miltenyi-Biotech, Bergisch-Gladbach, Germany). CD34 -enriched or CD3 -depleted HSPCs were incubated with a murine anti-human CD3 antibody (clone Okt3, BioXCell, NH, USA) at 5µg / 100µl for 10 minutes at RT prior to injection into mice.
Generation and Analysis of MISTRG PDXs
Mouse breeding and xenografting: MIS h/h TRG mice with homozygous knockin-replacement of the endogenous mouse Csf1, Il3, Csf2, Tpo, and Sirpa with their human counterparts were bred to MITRG mice to generate human cytokine homozygous and hSIRPA heterozygous mice 14, 15 . NSG mice were obtained from Jackson laboratory. MIS h/m TRG (labeled MISTRG throughout the manuscript) and NSG mice were maintained on continuous treatment with enrofloxacin in the drinking water (0.27 mg/mL, Baytril, Bayer Healthcare). Newborn Flowcytometric Analysis: Engraftment of human CD45 + cells and their stem cell, progenitor, and mature myeloid, lymphoid, and erythroid or megakaryocytic subsets were determined by flowcytometry using antibody panels detailed in Supplementary Table 3 . In brief, cells were isolated from engrafted mice, blocked with human/murine Fc block, and stained with indicated combinations of antibodies. Data were acquired with Table 4 ). Images were acquired using Nikon Eclipse 80i microscope.
All animal experimentations were performed in compliance with Yale Institutional Animal Care and Use Committee protocols.
MSC Culture and Verification of Immunophenotype and Human Cytokine Expression
Human or mouse BM was cultured in Dulbecco's Modified Eagle Medium (DMEM, ThermoFisher, Wilmington, DE) supplemented with 20% FBS, Pen/Strep, and L-Glutamine. Non-adherent cells were removed after 24 hours of culture and MSC grown to confluency. Cells were expanded for a maximum of 5 passages and their immunophenotype confirmed by flow cytometry using antibody panels detailed in Supplementary Table 3 and analyzed on a LSR Fortessa. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) and reverse-transcribed with the ISCRIPT™ cDNA Synthesis kit (Bio-Rad). Primers for verification of cytokine expression are provided in Supplementary Table 5 . Reaction products were analyzed on 2% agarose gels. Q-RT-PCR was run in triplicates per standard protocol using the same primers.
Conventional Karyotyping and FISH
Conventional chromosome analysis was performed on flow-sorted human CD45 + cells from mouse BMs according to the Yale Clinical Genetics Laboratory standardized protocols. Routine FISH tests were performed using a MDS/AML panel of commercial probes for the 5q (EGR1 gene at 5q31), 7q (D7S486 at 7q31), 8q (MYC at 8q24) and 20q (D20S108 at 20q12) loci (Abbott Molecular, Des Plaines, IL). At last, only non-synonymous variants were kept. To extract the allele frequency of the variants, all nonsynonymous somatic mutations from all the samples associated with certain patients were aggregated. The allele frequency of each variant was assessed using Samtools mpileup.
Targeted Exome Capture, Sequencing, and Analysis
Cloning and Isogenic Cell Line Construction
To generate isogenic wildtype and mutant expressing cell lines the lentiviral plasmids pSLIK-IDH2-FLAG and pSLIK-IDH2-R172K-FLAG (a gift from Christian Metallo, Addgene plasmid ## 66806, 6680, 48 ) were used to transduce human erythroid leukemia cell (HEL) cell lines. To generate IDH2 R140Q mutant plasmid IDH2-WT-FLAG was amplified and cloned into pGEM®-T Easy Vector Systems (A1360, Promega, Madison, WI). IDH2 R140Q site-directed mutagenesis was preformed using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) with primers provided in Supplementary Table 5 and cloned into the pEN_TTmcs entry vector for recombination into the pSLIK-hygro lentiviral vector (kind gifts from Iain Fraser, Addgene plasmid # 25755 and # 25737, respectively, 49 
Statistical Analysis
Data was analyzed using Prism 7 (GraphPad Software, La Jolla, CA) with the use of Fisher's exact test, unpaired t-test, unpaired Mann-Whitney U test, one-way ANOVA Kruskal-Wallis test with Dunn's Multiple Comparison Test, or two-way ANOVA with Sidak's Multiple Comparison Test as indicated. P value was considered significant at values less than 0.05. Linear regression analyses were performed with R. Pearson correlation p-values were determined with the cor.test () function implemented in R.
Abbreviations
PB peripheral blood, BM bone marrow, IHC immunohistochemistry, H&E hematoxylin&eosin, S.E.M. Standard Error of the Mean. MDS-MLD Myelodysplastic syndrome with multilineage dysplasia, MDS-RS-SLD Myelodysplastic syndrome with ring sideroblasts with single lineage dysplasia, MDS-EB Myelodysplastic syndrome with excess blasts.
MSCs Mesenchymal stromal cells, HSC Hematopoietic stem cells, M-CSF macrophage colony stimulating factor, GM-CSF granulocyte-macrophage colony stimulating factor, THPO Thrombopoietin. n.s. not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. For detailed patient sample information see Supplementary Table 1 . 
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